ClinicalTrials.gg
RecruitingNCT06756906Updated Jan 3, 2025

Comparison of High Flow Nasal Oxygen and Nasal Cannula in Burn Patients Under Sedation

An observational study in Burn Injury, Hypoxia and Sedation, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Ankara City Hospital Bilkent · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Burns with a site in Turkey — 13 open to participants now, 17 under way, none of them phase 3. Burns · Turkey.

Planned enrollment
7th of 10
70 · median 97
Started
2024
with 1 other
Observational
10 of 43
2 open now
Primary completion
2025-01
later than 2 of 16 live
Registered
25th of 43
by date
Lead sponsor
1 of 43
Ankara City Hospital Bilkent

Among the 43 studies in Burns with a site in Turkey, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2024, is one of 10 observational ones, reaches primary completion later than 2 of the 16 other live ones, and was the 25th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

13 of the 43 studies in Burns with a site in Turkey are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Burns with a site in Turkey, or all of them as a file.
02

Study summary

Burn-related pain is severe and often difficult to manage. Burn patients often require high doses of opioids and anxiolytics. Anesthetic agents used during sedation such as benzodiazepines, propofol and opioids can cause respiratory depression, predisposing patients to hypoventilation and hypoxemia due to airway obstruction. Oxygen is administered to patients with a standard nasal cannula during sedation. High Flow Nasal Oxygen (HFNO) helps to improve the oxygenation of patients with respiratory distress by delivering high flow humidified oxygen through the nasal cannula at a high rate of up to 40-70 liters per minute. The aim of this study was to compare the effects of HFNO and nasal oxygen therapy in preventing hypoxemia in deeply sedated burn patients.

Read the detailed description

This research is an observational prospective case-control study conducted in the Burns Center of Ankara Bilkent City Hospital. The aim of the study was to compare standard nasal oxygen therapy with High Flow Nasal Oxygen (HFNO) therapy in terms of hypoxemia in patients undergoing surgery for minor and moderate burns under deep sedation. Volunteer patients over 18 years of age, in the ASA (American Society of Anesthesiology) I-III risk group, who will undergo burn operation will be included in the study. Patients will be informed about the scope of the study, possible risks and benefits before participating in the study, and informed consent will be obtained from all participants by signing the informed consent form.

A total of 70 patients will be included in the study. The study consists of 2 groups. Group 1: Standard nasal oxygen (n:35), Group 2: HFNO (n:35) Before starting induction, patients who will be given nasal oxygen will be preoxygenated with 100% oxygen for 3 min with an oxygen flow rate of 8 l/min. Patients who will receive HFNO will be preoxygenated with HFNO 40 l/min with FiO2 100% 3 min before induction. Patients will be premedicated with 1 mg iv midazolam and 1 mcg/kg fentanyl 1 min before induction. During the induction phase, 1% propofol-ketamine (0.5-1 mg/kg) will be administered and an additional dose of propofol-ketamine will be administered according to the patient's BIS value and the total drug dose will be noted. Non-invasive arterial blood pressure, heart rate, electrocardiogram (ECG), oxygen saturation, SpO2, BIS and NIRS values will be recorded before and every 5 minutes during the procedure. Patient demographics, total procedure time, amount of anesthetic agent used, heart rate and other clinical parameters will also be recorded. Ramsey sedation scale of the patients during the procedure and Aldrete scores at the end of the procedure will be evaluated. In case of apnea or desaturation, maneuvers such as patient stimulation, chin lifting, or increasing oxygen flow were performed and recorded.

The statistical package program SPSS 25.0 (Armonk, NY: IBM Corp.) will be used for data analysis. Descriptive statistics (frequency, percentage, minimum, maximum, mean, standard deviation, median, min-max, IQR) will be used. Pearson chi-square test, Fisher or Yates x2 tests will be used to compare qualitative data. The conformity of the data to normal distribution will be evaluated by Kolmogorov-Smirnov and Shapiro-Wilk tests, skewness-kurtosis and graphical methods (histogram, Q-Q Plot, Stem and Leaf, Boxplot). For normally distributed quantitative data, independent samples t test or one way ANOVA will be applied. For non-normally distributed data, Mann-Whitney U test or Kruskal-Wallis test will be used. Paired t test or Friedman test will be used to compare repeated measures. The relationship between variables will be evaluated by Pearson or Spearmans's Rho Correlation test. P\<0.05 will be accepted as statistical significance level.

03

Conditions studied

  • Burn Injury
  • Hypoxia
  • Sedation

Browse trials for

Keywords

  • HFNO
  • Sedation
  • burn injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients scheduled for burn treatment under sedation in Ankara City Hospital's Burn Center will be included

Eligibility criteria

Inclusion Criteria : Voluntary patients over 18 years of age -ASA(American Society of Anaesthesiologists) I-III risk scores Exlusion Criteria

Exclusion Criteria:

  • Intubation
  • Tracheostomies
  • Need for oxygen therapy due to preexisting disease
  • Pregnancy
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Standard nasal oxygen therapy

    Patients will be preoxygenated with 8L/min oxygen and will receive 3L/min oxygen throughout the procedure.

  • Group 2: High-flow nasal oxygen therapy (HFNO)

    Patients who will receive HFNO will be preoxygenated with HFNO 40 l/min with FiO2 100% 3 min before induction. Patients will receive HFNO 50 l/min with FiO2 50% throughout the procedure.

06

What researchers measure

Primary outcomes

  1. Oxygen saturation SpO2 levels of the cases in %

    Each patient will be monitored with an oxygen saturation probe and SpO2 levels of the cases will be recorded before induction of sedation and every 5 minutes, throughout the procedure. Hypoxemia will be detected.

    Time frame: Oxygen saturation levels will be recorded before induction and every 5 minutes throughout the procedure.

Secondary outcomes

  1. Number of interventions over procedure time

    In case of apnea or desaturation, airway interventions will be performed and recorded throughout the procedure.

    Time frame: Number of maneuvers performed throughout the procedure.

Other outcomes

  1. Systolic, diastolic and mean blood pressures will be recorded in mmHg

    Before induction patients will be monitored, and systolic, diastolic and mean blood pressures will be recorded before induction and every 5 minutes throughout the procedure.

    Time frame: Blood pressure monitorization will be performed induction and every 5 minutes throughout the procedure.

  2. Heart beat will be recorded in beats per minute

    Heart beats will be recorded before induction and every 5 minutes throughout the procedure.

    Time frame: Heart beat monitorization will be performed before induction and every 5 minutes throughout the procedure.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Service JA, Bain JS, Gardner CP, McNarry AF. Prospective Experience of High-flow Nasal Oxygen During Bronchoscopy in 182 Patients: A Feasibility Study. J Bronchology Interv Pulmonol. 2019 Jan;26(1):66-70. doi: 10.1097/LBR.0000000000000533. PubMed 30048415 ↗
  • Khanna P, Haritha D, Das A, Sarkar S, Roy A. Utility of high-flow nasal oxygen in comparison to conventional oxygen therapy during upper gastrointestinal endoscopic procedures under sedation: A systematic review and meta-analyses. Indian J Gastroenterol. 2023 Feb;42(1):53-63. doi: 10.1007/s12664-022-01308-6. Epub 2023 Feb 13. PubMed 36780095 ↗
  • Spence EA, Rajaleelan W, Wong J, Chung F, Wong DT. The Effectiveness of High-Flow Nasal Oxygen During the Intraoperative Period: A Systematic Review and Meta-analysis. Anesth Analg. 2020 Oct;131(4):1102-1110. doi: 10.1213/ANE.0000000000005073. PubMed 32925331 ↗

Individual participant data

Plan to share: Yes — Date will be shared after publication of the study.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Beginnning right after publication and ending 2 years after the publication of results

Access criteria: Data required for research will be shared

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jan 2025, 6 months after the start.

Of 58 non-industry observational studies under Burns, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's planned 6 months is below that.

Counting every sponsor, half of 70 studies reached it within 24 months; a quarter within 14 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 3, 2025
StartActual
Jul 15, 2024
Primary completionEst.
Jan 27, 2025
CompletionEst.
Feb 10, 2025
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06756906
Responsible party
Cihan Döğer (Assoc. Prof. MD, Ankara City Hospital Bilkent) — Principal investigator
First posted
Jan 3, 2025
Start date
Jul 15, 2024
Primary completion
Jan 27, 2025 (estimated)
Completion
Feb 10, 2025 (estimated)
Last update
Jan 3, 2025

Study contacts

Sümeyye Demirhan, MD
Contact
dmrhnsmyy@gmail.com
+905469353388
Cihan Doger, Assoc Prof
Contact
cihandoger@gmail.com
+905054884195
Ezgi Erkılıç, Assoc Prof
principal investigator · Ankara Bilkent City Hospital, Department of Anesthesiology
Huriye Bilge Tuncer, MD
principal investigator · Ankara Bilkent City Hospital, Department of Anesthesiology
Merve Akın, Assoc Prof
principal investigator · Ankara Bilkent City Hospital, Department of General Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion